Last reviewed · How we verify
Eque-cel CAR-T Therapy
Eque-cel CAR-T Therapy is a CAR-T cell therapy Biologic drug developed by Nanjing IASO Biotechnology Co., Ltd.. It is currently in Phase 2 development for Relapsed or refractory B-cell lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.
CAR-T cell therapy targets CD19-positive B cells
CAR-T cell therapy targets CD19-positive B cells Used for Relapsed or refractory B-cell lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Eque-cel CAR-T Therapy |
|---|---|
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CAR-T cells are genetically modified to express a chimeric antigen receptor that recognizes CD19, leading to the selective killing of CD19-positive B cells.
Approved indications
- Relapsed or refractory B-cell lymphoma
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis (PHASE2)
- Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eque-cel CAR-T Therapy CI brief — competitive landscape report
- Eque-cel CAR-T Therapy updates RSS · CI watch RSS
- Nanjing IASO Biotechnology Co., Ltd. portfolio CI
Frequently asked questions about Eque-cel CAR-T Therapy
What is Eque-cel CAR-T Therapy?
How does Eque-cel CAR-T Therapy work?
What is Eque-cel CAR-T Therapy used for?
Who makes Eque-cel CAR-T Therapy?
What drug class is Eque-cel CAR-T Therapy in?
What development phase is Eque-cel CAR-T Therapy in?
What are the side effects of Eque-cel CAR-T Therapy?
What does Eque-cel CAR-T Therapy target?
Related
- Drug class: All CAR-T cell therapy drugs
- Target: All drugs targeting CD19
- Manufacturer: Nanjing IASO Biotechnology Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory B-cell lymphoma
- Indication: Drugs for Relapsed or refractory diffuse large B-cell lymphoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing